Editorial scope: This guide addresses analytical evidence, documentation, and research-procurement literacy. Conclusions are limited to the records and methods discussed.

Start with the naming problem: FST344 is a precursor, not simply a 344-residue finished protein

Follistatin is a secreted, single-chain glycoprotein that binds several signaling proteins in the transforming growth factor-beta superfamily. The label ‘follistatin-344’ or ‘FST344’ usually refers to one of two alternatively spliced human precursor sequences. It should not be treated as a complete description of the mature protein in a vial.

The longer transcript encodes a 344-amino-acid preprotein. Removal of its amino-terminal signal peptide produces the 315-amino-acid mature core commonly called FST315. The shorter 317-amino-acid precursor yields FST288 after signal-peptide cleavage. Proteolytic processing can generate additional forms, including FST303, and glycosylation adds another layer of heterogeneity.

That distinction is central to reading the literature. A gene-transfer study labeled FS344 delivers genetic information intended to make cells express and secrete follistatin; it does not test a generic lyophilized ‘344’ protein sold by a research supplier. This article does not provide a dose, route, gene-transfer procedure, treatment recommendation, or human or veterinary protocol.

  • FST344: 344-residue precursor encoded by the longer transcript
  • FST315: mature long isoform after signal-peptide removal
  • FST317: shorter precursor produced by alternative splicing
  • FST288: mature short isoform after signal-peptide removal
  • FST303: a processed intermediate form reported in biological samples

Follistatin is a multi-ligand antagonist, not a myostatin-only blocker

Follistatin was first characterized through its ability to bind and neutralize activin. Later biochemical work showed direct, high-affinity interaction with myostatin and activity against other related ligands under defined experimental conditions. Structural studies show follistatin wrapping around ligand dimers and blocking surfaces needed for receptor engagement.

The broad biology matters. Myostatin is strongly associated with regulation of skeletal-muscle growth, but activins and related ligands participate in reproductive, endocrine, developmental, inflammatory, and tissue-maintenance systems. Describing follistatin simply as a muscle-building myostatin inhibitor removes the very interactions that make its translation complicated.

Binding does not prove that every ligand is neutralized equally in every tissue. Concentration, local extracellular matrix, cell-surface proteoglycans, isoform, glycosylation, and competing partners all influence what an assay result means in a living system.

FST288 and FST315 are biologically related but not interchangeable

Recombinant comparisons found that follistatin isoforms can bind activin with similar affinity while differing substantially in cell-surface association. FST288 binds heparan-sulfate proteoglycans more strongly, FST303 is intermediate, and FST315 is generally more soluble and is the major circulating form detected in human serum.

Those localization differences can change biological activity. An isoform that remains near a cell surface may influence locally produced ligands differently from a more freely circulating form. The longer acidic tail of FST315 contributes to these biochemical distinctions even though the isoforms share most of their sequence.

A catalog page that alternates among ‘FST344,’ ‘FST315,’ and ‘follistatin’ without explaining precursor processing is therefore ambiguous. The names overlap historically, but they do not always identify the same physical test article.

Cell and structural evidence establishes mechanism—not a clinical effect

Crystal structures and binding experiments support a receptor-blocking mechanism for follistatin-ligand complexes. Cell assays further show that isoform-dependent surface binding can alter the neutralization of endogenous activin, myostatin, and selected bone morphogenetic proteins.

These studies are valuable for identity and mechanism. They cannot establish that a supplier material is correctly folded, biologically active, comparable to endogenous FST315, or safe in an organism. They also cannot determine whether broad ligand interception would produce a favorable balance of effects in a person.

Animal findings often come from gene expression, not purified-protein exposure

Several muscle studies changed follistatin expression genetically. Transgenic mice and pigs, for example, were engineered to overexpress follistatin in selected tissues, and investigators reported increased skeletal-muscle mass or altered fiber size. These models demonstrate what sustained biological production can do under controlled genetic conditions.

They do not establish the effect of an externally supplied recombinant protein. Gene expression determines where, when, and for how long cells make the protein; vector design and promoter choice add variables that a purified-material experiment does not share. Results from a transgene cannot be transferred to a vial based only on the word ‘follistatin.’

Nonhuman-primate research tested AAV-FS344 gene delivery

A frequently cited cynomolgus-macaque study used an adeno-associated viral vector carrying the human FS344 coding sequence. The investigators reported durable increases in the size and strength of targeted muscles and did not identify abnormal changes in the examined major organs during the reported follow-up.

This was a gene-delivery experiment, not a trial of a bottled FST344 protein. The vector, expression cassette, transduced cells, local production, immune response, and follow-up all belong to the test article. The result cannot authenticate or predict the behavior of a separately manufactured recombinant protein.

Human evidence is limited to small gene-transfer programs

The clearest peer-reviewed human evidence comes from small, early studies using AAV vectors that encoded FS344. A phase 1/2a Becker muscular dystrophy study included six participants. Some participants improved on the six-minute walk test and biopsy findings were reported, while others showed little or no functional change. The trial was uncontrolled and designed primarily as proof of principle, so efficacy conclusions remain limited.

A separate study in six people with sporadic inclusion body myositis reported changes in walking performance and muscle-biopsy findings after FS344 gene transfer. It used a small open-label design, nonrandomized external comparators, and an exercise program for some participants. A published critique argued that the design could not support a clear efficacy claim. The investigators published a reply, leaving the interpretation contested rather than settled.

A Duchenne muscular dystrophy registry study planned a larger cohort but enrolled three participants and posted results. These records document human investigation; they do not create an approved therapy or validate a research-market protein.

A completed plasmid study has no posted results

ClinicalTrials.gov also lists a completed open-label study in healthy adults using a plasmid intended to express the human FST344 gene. The record reports 43 enrolled participants, a study location in Honduras, and no results posted as of the November 19, 2026 review date.

A registry entry shows that a study was registered and describes what investigators intended to measure. Without posted results or a located peer-reviewed report, it cannot establish what happened, whether the intended protein was expressed as expected, or whether the intervention was safe or effective.

What the human evidence actually supports

Human research shows that FS344-encoding gene-transfer systems reached early clinical testing in small disease-specific cohorts. It does not establish an effect for isolated FST344 protein, healthy performance enhancement, age-related muscle loss, or any supplier material.

The trials were not large randomized efficacy studies. Their results are vulnerable to small samples, variable disease course, open-label assessment, exercise or rehabilitation effects, external comparators, and incomplete registry reporting. The test article was a gene-transfer platform whose risks and behavior include far more than the follistatin sequence alone.

  • Biochemical evidence: ligand binding and isoform-dependent localization
  • Animal evidence: transgenic expression and vector-mediated gene delivery
  • Human evidence: small early gene-transfer studies with major design limits
  • Research-vial evidence: a separate identity and manufacturing question

Published marketplace testing found serious identity problems

One analytical study purchased 17 black-market products labeled as follistatin-344 or follistatin-315. Only nine contained detectable follistatin; some of the others contained different growth-related peptides. The detected follistatin products were His-tagged and showed substantial oligomer formation.

That study does not prove that every current seller or lot is mislabeled. It does show why a product name, vendor chromatogram, or generic purity percentage is inadequate for this protein. A His-tagged recombinant construct is not identical to endogenous human follistatin, and oligomers may change both analytical behavior and biological interpretation.

Supplier documentation needs to identify the exact construct

For a research protein sold as FST344, the documentation should state whether the material is the full precursor, processed FST315, another truncation, or a tagged recombinant construct. It should name the expression system and disclose signal peptide, affinity tag, linker, cleavage site, and sequence boundaries.

Protein identity should be supported by more than a nominal mass. Orthogonal evidence may need to address intact mass or peptide mapping, disulfide connectivity, glycosylation, monomer and oligomer state, fragments, charge variants, host-cell proteins, residual DNA, and a fit-for-purpose ligand-binding or cell-based potency assay.

HPLC area purity cannot establish correct folding, ligand neutralization, mature isoform, glycan profile, aggregation, sterility, endotoxin, or equivalence to the protein produced in an AAV gene-transfer study. Those are separate attributes requiring separate evidence.

  • Sequence boundaries and whether the signal peptide is present
  • Expected mature product: FST315, FST288, or another construct
  • Expression host, purification process, and all engineered tags
  • Monomer, oligomer, aggregate, and fragment evidence
  • Glycosylation and other product heterogeneity where relevant
  • Lot-specific potency, impurity, sterility, and endotoxin records when claimed

Regulatory status and evidence bottom line

FDA records show investigational and orphan-drug activity around follistatin gene transfer, but the cited orphan-designation records state that those products were not FDA approved for the orphan indications. FDA also emphasizes that marketing a gene-therapy product requires an approved biologics license application.

Follistatin-344 is best understood as a precursor and gene-expression label within a complex isoform system. Cell, animal, primate, and small human gene-transfer studies support biological activity, while human efficacy remains unresolved. None of that evidence authenticates a research-vendor vial or makes purified FST344 interchangeable with an FS344-encoding vector.

FAQ: Are Follistatin-344 and Follistatin-315 the same?

They are related labels, but not literally the same sequence length. FST344 denotes the longer precursor; after its signal peptide is removed, the mature core is commonly called FST315. A supplier should state which physical construct is actually present.

FAQ: Have FST344 products been tested in humans?

FS344-encoding gene-transfer systems have been tested in small human studies. Those studies do not test or validate ordinary research-vendor protein vials. The vector, expression cassette, cellular production, and follistatin sequence are all part of the gene-therapy test article.

FAQ: Is Follistatin-344 FDA approved?

No FDA-approved FST344 protein or FS344 gene-transfer product was identified in the official records reviewed for this article. An orphan-drug designation, IND-associated trial, or ClinicalTrials.gov registration is not marketing approval.

Sources and further reading

Primary and standards-based sources used to frame this educational overview:

Explore related resources

Peptide Due Diligence Research Brief

Keep the evidence in view.

Receive concise briefings on analytical testing, documentation quality, supplier transparency, and new additions to the research library.

By subscribing, you agree to receive PDD research emails. Unsubscribe at any time.

Already subscribed? Get your free field guide.

Continue your due diligence